Beijing Junzheng stated on an interactive platform that the company has seen relatively significant price increases for DRAM, with NAND flash also undergoing price adjustments to varying degrees, and prices for computing chips also rising.
Source:富途快讯 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Liquidity Crunch in Cryptocurrency Mining: Causes and Analysis of the Current Situation in 2026
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
5
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
6
Israeli West Bank Settler Tells BBC Attacks on Palestinians Are Justified as Revenge, Equating One Jewish Life to "10 Million" Palestinians
-
7
ETH2X-FLI-P: An Analysis of the 2x Leveraged Ethereum Index Token on Polygon
-
8
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
9
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
10
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
Markets Today
Recommended Reading







